The first International Meeting on Apheresis was held in Dyon in 1984. At the congress it became clear that both the technical and therapeutic sides developed very rapidly and it appeared fruitful to bring together the investigators of the different countries working in the areas. At that time immunology had come to pervade many clinical specialities, and hemapheresis, especially plasmapheresis was considered a therapeutic tool in many immunological diseases which hitherto had proved to be fatal. New methods to identify certain antibodies and circulating immune complexes in the serum and the possibilities to remove them from the blood by several techniques (filtration, centrifugation, immunoabsorp tion) led to an almost uncontrolled use of plasma exchange in a variety of diseases. Since then the technical possibilities of this technique were further recognized, as was the impact of immunology on many diseases, and the possibilities to collect specific components for therapeutic pur poses. But also we became aware of the limited contributions of anec dotal data on successes or failures of apheresis as adjuvant treatment. Therefore international prospective studies were initiated to make critical assessment possible of apheresis in various diseases."

Blood Science is a relatively new discipline which merges biochemistry, haematology, immunology, transfusion science and genetics. This bringing together of traditional disciplines requires a corresponding change in education and training for healthcare scientists and Blood Science: Principles and Pathology is written in response to this emerging need. An introduction to the subject and an overview of the techniques used in blood science are followed by a series of chapters based on groups of analytes investigated in blood - red blood cells, white blood cells and platelets, followed by the constituents of plasma, including waste products, electrolytes, glucose, lipids, enzymes, hormones, nutrients, drugs, poisons and others. Each chapter is supported by learning objectives, summaries and further information, and a focus is given to chapter specific case studies with interpretation to demonstrate how laboratory data in conjunction with clinical details is utilised when investigating patients with actual or suspected disease. Finally, a separate chapter offers more detailed case reports that integrate the different aspects of blood science. Undergraduate students taking blood science modules as part of their BSc programmes in Biomedical and Healthcare Sciences will appreciate the level of integration between clinical biochemistry and haematology. In addition, this book will provide suitable initial reading for those students embarking on blood science modules on MSc programmes and will be of value to new graduates entering the profession and starting their career in blood science departments by supplementing practice-based training with the required theoretical underpinning. This book is approved by the Institute of Biomedical Science and written by its expert writers, many of whom work on the Institute s advisory panels.

Phase I trials are a critical first step in the study of novel therapeutic approaches. They follow years of development in the laboratory, and precede Phase II and III trials where testing of the drug becomes more focused yet is conducted on a wider scale. The primary goals of Phase I trials are to identify the recommended dose, schedule and pharmacologic behaviour of new agents or new combinations of agents, and to describe the adverse effects of treatment. In cancer therapeutics, such studies have particular challenges. In general, because of the nature of the effects of treatment, most studies are conducted in patients with advanced malignancy, rather than in healthy volunteers. Furthermore, the endpoints of these trials are usually measures of adverse effects, but increasingly investigators are interested in assessment of the effects of new drugs on their molecular target. These factors render the design, conduct, analysis and ethical aspects of Phase I cancer clinical trials unique. This book provides a practical guide to Phase I cancer trials and is appropriate for oncology trainees or specialists interested in understanding cancer drug development. Topics covered include preclinical requirements needed for first-in-man investigation of new agents, principles and statistical design, ethical considerations of Phase I studies, pharmacokinetics, pharmacodynamics, and studies in special populations. Practical information on protocol development, study activation and conduct, as well as how to write reports of the results, are incorporated. Numerous appendices offer document templates to use in Phase I study development, and examples from actual Phase I trials are interspersed throughout, making this a true 'hands-on' guide. In an exciting time in cancer research, as the number and type of new potential anti-cancer drugs is increasing dramatically, this book provides much needed information on the first stage in getting a drug approved.

Anemia in the elderly has been properly defined as the silent epidemic, representing 3 million people in the United States aged 65 years and older. Incidence and prevalence of this condition increase with age. It differs in its etiology, pathogenesis and treatment from anemia in children and younger adults. Anemia is associated with reduced survival, increased risk of functional dependence and hospitalization, increased risk of congestive heart failure and stage renal disease and cognitive disorders. Approximately 70% of anemia in older individuals is reversible.

For more than 30 years, the highly regarded Secrets Series (R) has provided students and practitioners in all areas of health care with concise, focused, and engaging resources for quick reference and exam review. Pediatric Hematology & Oncology Secrets, 2nd Edition, offers practical, up-to-date coverage of the full range of essential topics in this dynamic field. This highly regarded resource features the Secrets' popular question-and-answer format that also includes lists, tables, pearls, memory aids, and an easy-to-read style - making inquiry, reference, and review quick, easy, and enjoyable. The proven Secrets Series (R) format gives you the most return for your time - succinct, easy to read, engaging, and highly effective. Fully revised and updated, including discussions of supportive care of children with cancer and psychosocial aspects of care. New chapters on Precision Medicine and Systems Biology; Health Equity and Disparities in Pediatric and Adolescent/Young Adult Oncology; Transfusion Medicine; Neoplastic Hematopathology; Hemophagocytic Lymphohistiocytosis; and more. Top 100 Secrets and Key Points boxes provide a fast overview of the secrets you must know for success in practice and on exams. Bulleted lists, mnemonics, practical tips from global leaders in the field - all providing a concise overview of important board-relevant content. Portable size makes it easy to carry with you for quick reference or review anywhere, anytime. Enhanced eBook version included with purchase. Your enhanced eBook allows you to access all of the text, figures, and references from the book on a variety of devices.

'The test cases are particularly variable, including pertinent management tips in the answers. The book also contains a set of useful self-assessment questions. Being pedantic, this could now benefit from an increase in the proportion of 'Single Best Answer Questions', now ubiquitous in undergraduate assessment. This will continue to be on my local recommended reading list, particularly for those students wanting a thorough understanding of Haematology, from the laboratory through to basic management. It would also be a good text for those starting a career in Haematology, such as Physician Associates and doctors early in their training.'British Journal of HaematologyThis second edition of Haematology: A Core Curriculum is written by a haematologist with more than forty-five years of experience in teaching haematology to medical students and whose pedagogical and writing skills are widely admired within the field.The textbook takes a useful, practical approach, incorporating self-evaluation questions and learning objectives that give students the information needed to understand the topic and clear indications of the core knowledge required to progress within the field of haematology. Themes covered include clinical haematology and the scientific basis of the discipline and the causes and pathogenesis of haematological disorders as well as how conditions are diagnosed and treated.Haematology closely follows the Imperial College London curriculum but medical students, trainee nurses and biomedical science students from other institutions will find the textbook equally suitable, since it includes the core student haematology curriculum as recommended by the Royal College of Pathologists.Related Link(s)

There is no field of medicine in which advances in therapy have been so closely linked to a better understanding of molecular medicine than in the area of hematologic malignancies. For example, recent insights into the understanding of Epstein-Barr virus have led to new treatment options for patients with posttransplant lymphoproliferative disorders, as discussed in the chapter by Dr. Richard Ambinder et al. Similarly, Drs. Slack and Gallagher discuss the explosion of recent information regarding the molecular pathogenesis of acute promyelocytic leukemia. This particular morphologic subtype of acute my- eloid leukemia warrants separate discussion because of our increased under- standing of the pathogenesis of leukemia, as well as the dramatic advances in outcome that have occurred with differentiation therapy provided by the vitamin A derivative aW-trans retinoic acid, as discussed in the chapter by Drs. Frankel and Powell. New approaches in the therapy of diffuse aggressive lymphomas in relationship to prognostic factors are discussed by Drs. Koc and Schenkein. Novel approaches to cutaneous T-cell lymphomas are discussed by Drs. Foss and Kuzel. Drs. Fonseca and Greipp discuss prognostic factors in myeloma, which are potentially important since they may serve to identify patients who may benefit from aggressive therapy such as bone marrow trans- plantation, which is discussed in the chapter by Dr. David Vesole. State-of-the-art reviews are provided in the chapters on AIDS-related non- Hodgkin's lymphoma by Drs. Volm and Von Roenn, adult acute lympho- blastic leukemia by Drs.

Linked by Blood: Hemophilia and AIDS recounts the factors responsible for the widespread infection of people with hemophilia by Human Immunodeficiency Virus (HIV)-contaminated blood and offers a prescription for addressing the challenges of future viral epidemics. The book describes the impact of AIDS on people with hemophilia, their families, and caregivers. The collection, processing, and distribution of blood in the early years of the HIV epidemic are described, including the failure of regulatory agencies to promulgate effective rules to safeguard the blood supply. The contributions of individuals and organizations that mitigated the epidemic are recognized. Linked by Blood presents recommendations for addressing the myriad medical, social, and economic challenges posed by blood-borne viral infections (AIDS, Ebola, MERS) that periodically sweep through large segments of our population.

Lanzkowsky's Manual of Pediatric Hematology and Oncology, Sixth Edition, is a comprehensive book on patient management, replete with algorithms and flow diagrams on diagnosis and management. Reflecting the considerable advances in the treatment and management of hematologic and oncologic diseases in children, the sixth edition of this successful clinical manual has been entirely updated to incorporate all current treatment protocols, new drugs, and management approaches. Its concise and easy-to-read format will enable readers to make accurate diagnoses and permit them to treat patients without having to reference larger medical textbooks. Based on the new standards of genetic classification and prognostic information that have arisen in the past five years, the sixth edition includes two new chapters (Diagnostic, Molecular, and Genomic Methodologies for the Hematologist, Transfusion Medicine) and several new expanded chapters that were previously sections in consolidated chapters (Myelodysplasia, Myeloid Leukemias, Lymphoid Leukemias, Hemolytic Anemia, and Disorders of Coagulation).

Chelation Therapy in the Treatment of Metal Intoxication presents a practical guide to the use of chelation therapy, from its basic chemistry, to available chelating antidotes, and the application of chelating agents. Several metals have long been known to be toxic to humans, and continue to pose great difficulty to treat. These challenges pose particular problems in industrial settings, with lead smelting known to be associated with hemopoietic alterations and paralyses, and the inhalation of mercury vapor in mercury mining being extremely detrimental to the central nervous system. Clinical experience has demonstrated that acute and chronic human intoxications with a range of metals can be treated efficiently by administration of chelating agents. Chelation Therapy in the Treatment of Metal Intoxication describes the chemical and biological principles of chelation in the treatment of these toxic metal compounds, including new chelators such as meso-2,3-dimercaptosuccinic acid (DMSA) and D,L-2,3-dimercapto-1-propanesulfonic acid (DMPS).

The theme of this 14th International Symposium on Blood Transfusion is closely related to the work and scientific contributions of the Dutch cryobiology pioneer Dr. Herman W. Krijnen of the Dutch Red Cross Central Laboratory. Dr. Krijnen was known and respected in the national and interna tional blood transfusion community as an extremely competent scientist and a beloved and admired colleague. Dr. Krijnen was intentionally honoured with the invitation to open this symposium on cryopreservation and low temperature biology in blood transfusion and be the guest of honour at this event. Unfortunately, Dr. Krijnen suddenly died on the first of June 1989. In honour and mem ory of Dr. Krijnen this symposium will therefore be dedicated to him. Since the lOth International Symposium on Blood Transfusion in 1985 highlighted the theme of "Future developments in blood banking," major changes have occurred in the blood banking world. Most of these changes were forced upon the Blood Banks by the fear of spreading AIDS through contaminated donations. This not only led to the wide spread testing of blood, but also to a more appropriate counselling of the community and the blood donors in specific. Additionally, virus inacti vation techniques were introduced for those components derived from multiple donations and intended for a regular transfusion in haemophi lia patients and others."

This book provides clear instruction on the surgical treatment of joint problems in adult hemophilia patients. The procedures applicable to specific joints, including the shoulder, elbow, hip, knee and ankle, are carefully reviewed with the aid of high-quality illustrations. The surgical treatment of articular hemophilic pseudotumors and bone cysts is also considered. In addition, clinically relevant information is provided on a range of topics, such as the treatment of hemophilic hemarthrosis, the imaging of hemophilic joints, hematological perioperative management, anesthesia, rehabilitation and pharmacoeconomics. Finally, the controversial issues of postoperative thromboembolic prophylaxis and the role of COX-2 inhibitors in hemophiliacs are reviewed. The guidance provided draws on both the authors' extensive personal experience and an in-depth review of the pertinent literature. The book offers an excellent, up-to-date account of knowledge on musculoskeletal problems and approaches to joint surgery in adults with hemophilia. It will be of value to orthopedic surgeons, rehabilitation physicians, hematologists, radiologists and pharmacy researchers.

Blood Tests Made Easy is a quick reference guide designed to bring medical students up to speed when interpreting blood tests on their clinical placements. Small enough to be carried and quickly referenced on the go, this book covers everything you need to know when interpreting bloods, including the main abnormalities you are likely to encounter. Rather than focusing on theory or physiology, it is designed to provide an easy-to-follow guide to support clinical decision making. This latest addition to the Made Easy series will fill knowledge gaps on blood test interpretation, becoming a valuable asset both for medical students and, later, as a reference guide to increase junior doctors' confidence on the wards. Relevant to real life - material laid out like real hospital laboratory tests Easy to use - information presented in a clear and accessible format Case studies and multiple-choice questions to aid revision Portable for easy access on the wards

This new edition of an essential text for all those working within transfusion and blood banking is now even more biologically and clinically relevant, incorporating the latest information on the genes for various blood groups and including greater content on the functional significance of blood groups. The book covers techniques used in blood grouping, troubleshooting and quality assurance and integrates serology with molecular biology, marrying the basic understanding at the genetic level with a cellular understanding of the red blood cell membrane. Now in full colour throughout.

This book contains the proceedings of a symposium on the use of synthetic substrates in clinical blood coagulation assays, which was held at the University of Leuven, Belgium, on March 1st, 1980. This meeting was organized in order to exchange and discuss recent develop ments and applications in this field. Advantages and disadvantages of synthetic substrates are discussed, while expert workers report on their practical experience with the use of chromogenic substrates in routine assays for blood coagulation and fibrinolysis. The indications when to perform antithrombin III, a2-antiplasmin, factor X and factor II determinations are discussed. For each of the determinations a critical evaluation of the chromogenic assay as compared to the classical assay is presented. The clinical relevance of these assays for anticoagulated and cirrhotic patients, detection of vitamin K deficiency, monitoring heparin therapy and the fibrinolytic system are discussed. Recent developments in the use of fluorogenic substrates for the assay of low concentrations of fibrin olytic activators are presented. Taking into account all practical, medical and economical con siderations an answer is prepared to the question "Are synthetic sub strates to be recommended for routine use?." To make this symposium useful, rapid publication of the proceedings has been undertaken. We are grateful to the participants in this meeting for their co operation and for their willingness to provide manuscripts of their presentations. The manuscripts provided by C. Kluft and H.H.D.M."

We are pleased to present our readers the proceedings of the International symposium on "New Aspects of Human Polymorpho- nuclear Leukocytes" which was held in Freiburg im Breisgau, FRG, from October 26-28th, 1989. The meeting provided an unique framework for close interaction between scientists from various disciplines, including bioche- mistry, biology, physiology, pathology, clinical chemistry, hematology, gynecology, surgery, intensive care medicine, nephrology, rheumatology, and infectious diseases. We would like to express our gratitude and appreciation for all those who have stimulated, encouraged, and supported us to hold the symposium in Freiburg. This endeavor could not have been possible without the generous financial support of Asid- Bonz (Boblingen), Bayer AG (Leverkusen), Bayropharm GmbH (Koln), Baxter (Munchen), Ciba-Geigy (Wehr/Baden), Cilag GmbH (Sulzbach), Fresenius AG (Oberursel), Gambro (Martinsried), Gry-Pharma GmbH (Kirchzarten), Hoechst AG (Frankfurt), Hospal (Nurnberg), Knoll AG (Ludwigshafen), Lederle-Cyanamid (Wolfratshausen) , E. Merck (Darmstadt), MSD Sharp and Dohme GmbH (Munchen), Pfizer GmbH (Karlsruhe), and Kabi/Pfrimmer (Erlangen). We are indebted to Mrs. I. Szkibik for her invaluable ass i- stance both with the organization of the meeting and the pre- paration of the manuscripts.

Currently blood is a volatile issue. The safety of blood and the quantification of transfusion risks have been dominant themes that have stimulated the development of alternative approaches in this rapidly developing area. In clinical medicine conventional blood and its components are used in supportive therapies dependent on the choice of apparent uncritical trigger factors. A compounding factor is depth of prospective clinical trials for evidence. Such trials in critical care areas would be of enormous value, not only in recording adverse effects and under-transfusion, but also indicating the value of decision analysis and cost-effectiveness in transfusion practice. Alternative approaches include the use of cytokines, growth factors, humanised monoclonal antibodies, recombinant plasma factors, and buffy coat derived natural human interferons. These are being increasingly implemented in the clinic. Solutions for oxygen transport are being developed and fibrinogen coated microcapsules are being investigated for thrombocytopenia. In surgical patients, various crystalloid and colloid combinations are explored as volume replacements. To avoid allogeneic transfusions, beneficial blood saving methods include various strategies, such as autologous deposits, normovolemic haemodilution and various agents including aprotinin, tranecamic acid, desmopressin and erythropoietin, but their use in hospital shows considerable variations. That umbilical cord blood could be a significant source of allogeneic stem cells in related and unrelated transplantation is illustrated by the increasing number of cord blood banks in Europe and elsewhere. Future blood resources are likely to face several challenges: immediate challenges relate to increased regulatory and political oversights; intermediate solutions would offer some improvements in public health and alleviate public fear but probably not address the economic challenges thrust upon the medical care system. As we approach the year 2000, the major concerns about transfusion medicine remain its logistics, safety and effectiveness. This theme is presented in the proceedings of the 22nd International Symposium on Blood Transfusion, developed in 21 up-to-date topics, collected and discussed in four sections. This book will be of timely value to students, professionals and all others interested or involved in the field of transfusion medicine, whether clinical or related.

th America th America

This fully illustrated text is an essential guide for trainees in Haematology and Medicine studying for higher examinations, as well as for professionals wishing to expand their knowledge or revalidate. The book contains over 100 illustrated cases covering the whole field of malignant and non-malignant haematology, including coagulation problems and infectious diseases. Each case contains a set of questions written by two Royal College examiners, with answers on the reverse page. Readers can make differential diagnoses and devise treatment plans and prognoses, before turning the page to read the experts' detailed answers. The cases are presented in random order - just as they would be in real life - and are of varying lengths and degrees of difficulty, accompanied by hundreds of colour photomicrographs, photographs, and x-rays. This new edition is revised and updated, with new cases, images, and tables.

Infections are among the most frequent complications in patients with hematological malignancies and in those undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation. A profound knowledge on the epidemiology, diagnostic approaches, treatment modalities and prophylactic strategies is essential for the clinical management of these complications in patients who are often severely immunocompromised owing to their underlying diseases and in particular, the intensive myelosuppressive chemo and immunotherapy. This textbook provides a clinically oriented, compact and up-to-date overview on infections in hematology patients and their management. The typical pathogens to be considered in different subgroups of patients are identified and further aspects of the microbiological background are explored. Clinical, imaging, and laboratory-based diagnostic techniques are discussed and therapeutic strategies appropriate to different situations are then presented, with due attention to the pitfalls, toxicities and interactions that can arise during antimicrobial treatment. Strategies to prevent infection are also outlined, encompassing antimicrobial prophylaxis, isolation procedures, hospital hygiene, protective immunization and the use of hematopoietic growth factors.

This book, written by respected experts, discusses in detail the latest developments in targeted therapy for hematologic malignancies using small molecules. It covers a wide range of small molecules including tyrosine kinase inhibitors, immunomodulatory drugs, the IDH-2 inhibitor enasidenib, the BCL-2 inhibitor venetoclax, and the proteasome inhibitor carfilzomib. For each molecule, aspects such as the chemical structure, mechanism of action, drug targets, drug interactions, preclinical studies, clinical trials, treatment applications, and toxicity are discussed. Extensive research into the molecular mechanisms of cancer has heralded a new age of targeted therapy. The field of precision cancer therapy is now growing rapidly, and the advances being made will mean significant changes in the treatment algorithms for cancer patients. Numerous novel targets that are crucial for the survival of cancer cells can be attacked by small molecules such as protein tyrosine kinase inhibitors. An accompanying volume addresses the use of small molecules in oncology, and the two volumes together represent the third edition of the book originally published under the same title.

As an essential guide to paediatric haematology, this concise text offers a quick and reliable source of practical information for clinicians. Covering all blood disorders in children, the contents are structured to include all the major disease groups and include introductory chapters on normal haemopoiesis, normal coagulation, infections and transfusion. Whilst the text focuses on practical management, sufficient background information is given to enable trainees to care effectively for patients. Essential Paediatric Haematology is an ideal text for haematologists and paediatricians in training and a valuable source of reference for other health care professionals.